DUBLIN, Oct. 14, 2024 (GLOBE NEWSWIRE) — “Australia and New Zealand Research Antibodies Market by Product, Specificity, Technology, Source, Application, End-Use and Country, 2024-2030 The “Size, Share and Trend Analysis Report” report has been added to ResearchAndMarkets.com’s offering.
The Australia and New Zealand research antibodies market size is expected to reach USD 77.6 million by 2030, at a CAGR of 4.8% from 2024 to 2030. The driving factors for this market include increasing research and development initiatives by biopharmaceutical and biotechnology companies, increasing number of government agencies, etc. Investment in research and development, growth in neurobiology and stem cell research.
Increasing R&D investments and research activities by various pharmaceutical and biotechnology companies to develop new innovative products are expected to drive market growth. For example, in March 2019, the federal government announced a partnership with Stem Cells Australia to support research and development around stem cells and explore new ways to treat a range of life-threatening conditions including stroke, congenital heart disease and kidney disease. Invested US$150 million in the University of Melbourne. disease.
Growth in stem cells and neurobiology-based research is expected to boost the market during the forecast period. Australia has a number of neurobiology-based research institutions. For example, the Australian Center of Excellence in Neuromuscular Disorders Research is a collaboration between neuromuscular experts.
Continuous new product launches are expected to drive market growth during the forecast period. For example, in April 2019, Bio-Rad launched a series of isotype-specific secondary antibodies (IgG1, IgG2a, and IgG2b). These products are used for improved signal transduction as well as specificity in ELISA, imaging, Western blotting, and flow cytometry.
Increased adoption of strategies such as collaborations and acquisitions by key market players is expected to drive market growth. For example, in March 2016, Thermo Fisher Scientific Inc. announced the acquisition of Affymetrix, Inc. This strategic acquisition was aimed at strengthening the company’s position in the bioscience field and expanding its antibody portfolio.
New Zealand has invested heavily in research and development to promote trade in the biotechnology sector. According to the Research, Science and Innovation System Performance Report, the country’s total spending on research and development in 2016 was estimated at 1.23% of GDP. This funding was provided by both public and private New Zealand companies. Data from the same source also shows that the country’s scientific system is highly productive in publications per researcher, with more than US$653,400 spent on research and higher education.
Australia and New Zealand Research Antibodies Market Report Highlights
Primary antibodies accounted for the dominant share in the product segment in 2023. This may be due to the wide use of these antibodies in research. Monoclonal antibodies accounted for the largest share in the type segment in 2023, mainly due to their efficient staining properties and high specificity of antigen detection.Western blotting accounted for the largest share in the technology segment due to the increasing demand for rapid diagnostic methods. Based on technology, ELISA is expected to witness the highest CAGR during the forecast period due to the use of traditional polyclonal antibodies in sandwich ELISA Based on sources, mice mice are used for research purposes Due to the convenience of use in producing antibodies, this segment captured the largest share in the Australia and New Zealand research antibodies market in 2023.
The key players in the Australia and New Zealand research antibodies market are:
Abcam Bio-Rad Laboratories BD Mercron The Thermo Fisher Scientific Cell Signaling Technology F. Hoffman La Roche Agilent Technologies Revvity
This report covers:
Market intelligence to enable effective decision making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trends analysis Segment and regional revenue forecasts for market assessment Competitive strategies and market share analysis to stay ahead of the curve List of product innovations in
Key attributes:
Report attribute details No. Forecast period 2023 – 2030 Estimated market value in 2023 (US$) 55.7 million US dollars Predicted market value by 2030 (US$) 77.6 million US dollar Average annual growth rate 4.8% Target region Australia, New Zealand
Main topics covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1.Market outlook
2.2. Segment outlook
2.3. Competitive Insights
Chapter 3 Australia and New Zealand Research Antibodies Market Variables, Trends, and Scope
3.1. Market introduction/system outlook
3.2. Market size and growth prospects (USD million)
3.3.Market trends
3.4. Australia and New Zealand Research Antibodies Market Analysis Tools
3.4.1. Porter’s analysis
3.4.2. PESTEL analysis
Chapter 4 Australia and New Zealand Research Antibodies Market: Product Forecast and Trend Analysis
4.1. Segment Dashboard
4.2. Australia and New Zealand Antibodies Market Research: Product Trend Analysis, USD Million, 2023 and 2030
4.3.Major
4.4.Secondary
Chapter 5 Australia and New Zealand Research Antibody Market: Specificity Estimation and Trend Analysis
5.1. Segment Dashboard
5.2. Australia and New Zealand Research Antibodies Market: Specificity Transfer Analysis, USD Million, 2023 and 2030
5.3. Monoclonal antibodies
5.4. Polyclonal antibodies
Chapter 6 Australia and New Zealand Research Antibody Market: Technology Forecast and Trend Analysis
6.1. Segment Dashboard
6.2. Australia and New Zealand Research Antibodies Market: Technology Trends Analysis, USD Million, 2023 and 2030
6.3. Immunohistochemistry
6.4. Immunofluorescence
6.5.Western blotting
6.6.Flow cytometry
6.7. Immunoprecipitation
6.8.Elisa
6.9.Others
Chapter 7 Australia and New Zealand Research Antibodies Market: Source Estimates and Trend Analysis
7.1. Segment Dashboard
7.2. Australia and New Zealand Antibody Research Market: Source Movement Analysis, USD Million, 2023 and 2030
7.3.Mouse
7.4.Rabbit
7.5. goat
7.6.Others
Chapter 8 Australia and New Zealand Research Antibodies Market: Application Estimation and Trend Analysis
8.1. Segment Dashboard
8.2. Australia and New Zealand Antibody Research Market: Application Trends Analysis, USD Million, 2023 and 2030
8.3. Infectious diseases
8.4. Immunology
8.5. oncology
8.6. Stem cells
8.7. Neurobiology
8.8. others
Chapter 9 Australia and New Zealand Research Antibodies Market: End-Use Forecast and Trend Analysis
9.1. Segment Dashboard
9.2. Australia and New Zealand Antibodies Market Study: End-use Transfer Analysis, USD Million, 2023 and 2030
9.3.Hospital
9.4.Other than hospitals
Chapter 10 Australia and New Zealand Research Antibodies Market: Country Estimates and Trend Analysis
10.1. Australia and New Zealand Research Antibodies Market Share, by Countries, 2023 and 2030, USD Million
10.2.Australia
10.3. New Zealand
Chapter 11 Competitive Environment
11.1. Recent developments and impact analysis by key market participants
11.2. Company classification
11.3.Company heat map analysis
11.4.Company Profile
11.4.1. Abcam Ltd.
11.4.2.Bio-Rad Laboratories, Inc.
11.4.3.BD
11.4.4. Merck KGaA
11.4.5. Lonza
11.4.6.Thermo Fisher Scientific Co., Ltd.
11.4.7. Cell Signaling Technology Co., Ltd.
11.4.8. F. Hoffman La Roche Co., Ltd.
11.4.9. Agilent Technologies Co., Ltd.
11.4.10. Liberty
For more information on this report, please visit https://www.researchandmarkets.com/r/evn97t.
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
Australia and New Zealand research antibodies market
